Eli Lilly and Company (NYSE:LLY) Stock Price Down 3.4% – Here’s What Happened

Shares of Eli Lilly and Company (NYSE:LLY) dropped 3.4% during trading on Wednesday . The company traded as low as $1,180.01 and last traded at $1,191.49. 2,977,720 shares changed hands during mid-day trading, a decline of 4% from the average session volume of 3,090,131 shares. The stock had previously closed at $1,233.66.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.S. FDA approved Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events—including cardiovascular death, nonfatal heart attack and nonfatal stroke—in adults with type 2 diabetes at high cardiovascular risk. The approval could support broader prescribing, payer coverage and sales growth for Lilly’s key diabetes and incretin franchise. Reuters: FDA approves Lilly’s Mounjaro to reduce cardiovascular risk
• Positive Sentiment: Lilly’s oncology business grew 11% in the first half of 2026, with newer medicines and pipeline candidates offering investors a potential source of growth beyond Mounjaro and Zepbound. Lilly’s oncology portfolio
• Positive Sentiment: The FDA cleared an Alzheimer’s blood test developed by Lilly and Roche, potentially making Alzheimer’s screening more accessible and strengthening Lilly’s broader diagnostics and Alzheimer’s strategy. Eli Lilly clears hurdle in Alzheimer’s fight
• Neutral Sentiment: Lilly advanced brenipatide into a Phase 3 depression study. The program could diversify the pipeline over the long term, but it remains dependent on future clinical results and regulatory approval. Lilly’s Brenipatide enters Phase 3
• Negative Sentiment: LLY has pulled back after recently reaching an all-time high, with profit-taking likely contributing to weaker sentiment. Concerns that employers and insurers may restrict coverage for obesity treatments such as Zepbound could also pressure expectations for long-term volume growth. Eli Lilly slides as GLP-1 coverage concerns weigh on sentiment
• Negative Sentiment: A Zepbound cost-savings study reported lower healthcare costs and fewer hospital visits, but criticism that it excluded the medicine’s price limits how strongly the results support Lilly’s payer negotiations. Separate legal disputes involving retatrutide also highlight broader enforcement and intellectual-property risks in the peptide market. Lilly’s cost-saving study leaves out Zepbound’s price

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on LLY. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Leerink Partners upped their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Barclays increased their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Finally, Bank of America raised their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,292.18.

Eli Lilly and Company Stock Down 1.2%

The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a market capitalization of $1.11 trillion, a P/E ratio of 39.43, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The stock’s fifty day simple moving average is $1,187.82 and its two-hundred day simple moving average is $1,064.57.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts expect that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 23.22%.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by company insiders.

Institutional Trading of Eli Lilly and Company

Several institutional investors have recently added to or reduced their stakes in LLY. Integrity Financial Corp WA increased its position in shares of Eli Lilly and Company by 1.3% during the second quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock worth $767,000 after buying an additional 8 shares during the period. Willner & Heller LLC grew its holdings in Eli Lilly and Company by 1.0% during the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company’s stock worth $1,100,000 after acquiring an additional 9 shares during the period. Aspiring Ventures LLC grew its holdings in Eli Lilly and Company by 3.7% during the 2nd quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock worth $306,000 after acquiring an additional 9 shares during the period. Wealthspan Partners LLC raised its position in shares of Eli Lilly and Company by 0.4% in the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock worth $2,543,000 after acquiring an additional 9 shares in the last quarter. Finally, Navigoe LLC raised its position in shares of Eli Lilly and Company by 8.7% in the 2nd quarter. Navigoe LLC now owns 113 shares of the company’s stock worth $135,000 after acquiring an additional 9 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.